Digest Réseau Comment ça marche
Réseau
/
Sociétés
No
Non vérifié

Novo Nordisk A/S

Ce que nous écrivons

FinanceIndustrie pharmaceutiqueManagement/Organisation d'EntreprisePolitique ÉtrangèrePublicité/Marketing/Médias/Communication

118 communiqués de presse

Voir tous les communiqués de presse
30/09/2026
Industrie pharmaceutique
Publicité/Marketing/Médias/Communication
Novo’s investigational obesity and diabetes drug CagriSema reduces ‘food noise’ and shows benefits in organ and bone health – EASD 2026
Source
Novo Nordisk A/S
Émetteur
GLOBENEWSWIRE
1.00
0
22/09/2026
Industrie pharmaceutique
Management/Organisation d'Entreprise
Novo and UNICEF expand partnership to support a healthier start for more than 80 million children
Source
Novo Nordisk A/S
Émetteur
GLOBENEWSWIRE
1.00
0
21/09/2026
Industrie pharmaceutique
Publicité/Marketing/Médias/Communication
Novo's CagriSema delivers superior weight loss versus tirzepatide in REIMAGINE 5 trial
Source
Novo Nordisk A/S
Émetteur
GLOBENEWSWIRE
1.00
0
21/09/2026
Industrie pharmaceutique
Publicité/Marketing/Médias/Communication
Highlights to be presented at Novo’s Capital Markets Day 2026
Source
Novo Nordisk A/S
Émetteur
GLOBENEWSWIRE
1.00
0
18/09/2026
Industrie pharmaceutique
Publicité/Marketing/Médias/Communication
Novo’s once-weekly Sogroya® (somapacitan) receives positive CHMP opinion in Europe for children with idiopathic short stature (unexplained shortness)
Source
Novo Nordisk A/S
Émetteur
GLOBENEWSWIRE
1.00
0
17/09/2026
Industrie pharmaceutique
Politique Étrangère
Novo: CHMP recommends EU approval of FREHEMGO® (denecimig), the first factor VIIIa mimetic offering monthly, once every two weeks and weekly dosing in a pre-filled pen, for the treatment of haemophilia A
Source
Novo Nordisk A/S
Émetteur
GLOBENEWSWIRE
1.00
0
16/09/2026
Industrie pharmaceutique
Management/Organisation d'Entreprise
Novo and Anthropic will collaborate to advance drug discovery with Claude
Source
Novo Nordisk A/S
Émetteur
GLOBENEWSWIRE
1.00
0
16/09/2026
Industrie pharmaceutique
Publicité/Marketing/Médias/Communication
Novo to share real-world and clinical data including Wegovy® pill, and cardiometabolic pipeline progress with next-generation amylin treatments at EASD 2026
Source
Novo Nordisk A/S
Émetteur
GLOBENEWSWIRE
1.00
0
14/09/2026
Industrie pharmaceutique
Publicité/Marketing/Médias/Communication
Novo Nordisk enters next chapter to bring better health to more people, supported by ‘Novo’ rebrand and updated corporate culture
Source
Novo Nordisk A/S
Émetteur
GLOBENEWSWIRE
1.00
0
07/09/2026
Industrie pharmaceutique
Publicité/Marketing/Médias/Communication
Novo Nordisk STEP Young phase 3 data: 40.4% of children living with obesity achieved a BMI below the obesity threshold with semaglutide and lifestyle modification
Source
Novo Nordisk A/S
Émetteur
GLOBENEWSWIRE
1.00
0

Détails du contact

Réseaux sociaux

Followers
0
Compatibilité
0